Seminars in Arthroplasty
Volume 20, Issue 4 , Pages 251-254 , December 2009

The Future of Thromboembolic Prophylaxis

  • Fred D. Cushner, MD

      Affiliations

    • Division of Orthopedics, Insall Scott Kelly Institute, Southside Hospital, Bay Shore, New York, USA
    • Corresponding Author InformationAddress reprint requests to Fred D. Cushner, MD, Insall Scott Kelly Institute for Orthopaedics and Sports Medicine, 301 E. Main St, Bay Shore, NY 11706
    • ,
  • Michael P. Nett, MD

      Affiliations

    • Insall Scott Kelly Institute, Southside Hospital, Bay Shore, New York, USA

References 

  1. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–2775
  2. Kakkar AK, Brenner B, Dahl OE, et al. RECORD2 Investigators Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomized controlled trial. Lancet. 2008;372:31–39
  3. Lassen MR, Ageno W, Borris LC, et al. RECORD3 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–2786
  4. Turpie AG, Lassen MR, Davidson BL, et al. RECORD4 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (Record 4): A randomized trial. Lancet. 2009;373:1673–1680
  5. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thromb Haemost. 2007;97:931–937
  6. Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The bistro II randomized trial. J Thromb Haemost. 2005;3:103–111
  7. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (bay 59-7939)—An oral, direct factor Xa inhibitor—For the prevention of venous thromoembolism in patients undergoing total hip replacement. Thromb Res. 2007;120:685–693
  8. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594–604
  9. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368–2375
  10. Fitzgerald RH, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty (A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin). J Bone Joint Surg Am. 2001;83:900–906
  11. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb/Hemost. 2009;15:377–388
  12. Patel VP, Walsh M, Sehgal B, et al. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am. 2007;89:33–38
  13. Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty (Pneumatic plantar compression and aspirin compared with aspirin alone). J Bone Joint Surg Am. 1996;78:826–834
  14. Gelfer Y, Tavor H, Oron A, et al. Deep vein thrombosis prevention in joint arthroplasties: Continuous enhanced circulation therapy vs low molecular weight heparin. J Arthroplasty. 2006;21:206–214
  15. Botteman MF, Caprini J, Stephens JM, et al. Results of an economic model to assess the cost effectiveness of enoxaparin, a LMWH versus warfarin for the prophylaxis of deep vein thrombosis and associated long term complications in total hip replacement surgery in the United States. Clin Ther. 2002;24:1960–1986
  16. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm. 2002;59:1750–1754
  17. Colwell CW: Thrombosis prevention in total hip arthroplasty: A novel compression device versus low –molecular weight heparin. J Bone Joint Surg (in press)
  18. Froimson MI, Murray TG, Fazekas AF. Venous thromoembolic disease reduction with a portable pneumatic compression device. J Arthroplasty. 2009;24:310–316
  19. Edwards JZ, Pulido PA, Ezzet KA, et al. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. J Arthroplasty. 2008;23:1122–1127

PII: S1045-4527(09)00061-3

doi: 10.1053/j.sart.2009.10.009

Seminars in Arthroplasty
Volume 20, Issue 4 , Pages 251-254 , December 2009

Article Tools